Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25147587 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1KMT2AKDM4ECARM1 | |
| SCHEMBL25147585 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD11B1KMT2AKDM4ECARM1 | |
| SCHEMBL3478180 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2HSD11B1KDM4ECARM1PRMT6 | |
| SCHEMBL6026443 | 0.82 | SLC18A3 (0.43) | KMT2AKDM4ECARM1PRMT6 | |
| SCHEMBL12423904 | 0.82 | DRD2 (0.43) | SMN1; SMN2CARM1PRMT6 | |
| SCHEMBL3419598 | 0.82 | PIK3CD (0.44) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL1842886 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2HSD11B1KDM4EEPHX1 | |
| SCHEMBL25075222 | 0.80 | CARM1 (0.37) | KDM4ECARM1PRMT6 | |
| SCHEMBL824152 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2HSD11B1KMT2AKDM4E | |
| SCHEMBL21919696 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2HSD11B1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440651-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8158625-B2 | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | HOFFMAN-LA ROCHE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 3309/4885HSD11B1 766/4885KMT2A 4144/4885 |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PI4K2B, PIK3CA, PIK3R2 | SMN1; SMN2 3259/4885HSD11B1 321/4885KMT2A 4048/4885 |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | SMN1; SMN2 4230/4885HSD11B1 3011/4885KMT2A 904/4885 |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK3, CDK1 | SMN1; SMN2 864/4885HSD11B1 1380/4885KMT2A 606/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | SMN1; SMN2 2248/4885HSD11B1 690/4885KMT2A 4343/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 3309/4885HSD11B1 766/4885KMT2A 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.